MicroRNA在慢性淋巴细胞白血病中的研究进展  

Research Progress of MicroRNA in Chronic Lymphocytic Leukemia——Review

作　　者：耿凌云[1] 王欣[1] 

机构地区：[1]山东大学附属省立医院血液科,山东济南250021

出　　处：《中国实验血液学杂志》2014年第1期255-258,共4页Journal of Experimental Hematology

基　　金：国家自然科学基金(81270598);山东省自然科学基金(ZR2012HZ003;ZR2009CM059);山东省科技发展项目(2010GSF10250)

摘　　要：微小RNA(microRNA,miRNA)是一类长约22个核苷酸的内源性、非编码单链RNA分子,广泛存在于真核生物中,并在多种物种间高度保守。它可通过碱基互补配对的方式识别靶mRNA并与之3'端非翻译区(3'UTR)结合,通过降解靶mRNA或抑制其翻译等方式,调节基因的转录后表达水平,影响生物个体生长、发育、疾病发生等过程。慢性淋巴细胞白血病(chronic lymphocytic leukemia,CLL)是一种B淋巴细胞恶性克隆增殖性疾病,起病隐袭,在发病个体、疾病进展、治疗反应、临床预后等方面存在很大的异质性。目前,越来越多的研究显示,miRNA的突变或者异常表达与CLL的发生、进展、预后、药物疗效等密切相关。复杂多样的miRNA在CLL中可能扮演着癌基因或抑癌基因的角色,某些miRNA甚至有可能成为CLL新的生物学标记物或者治疗靶点。本文就相关miRNA分子在CLL的发病、预后、治疗及耐药问题中的研究进展做一综述。MicroRNA （miRNA） is a small endogenous noncoding single-stranded RNA molecule with about 22 nucleotides,and the high conservation in a variety of species exists in most eukaryotes.miRNA can recognize and bind to the 3＇untranslated region （3＇UTR） of target mRNA via complementary base pairing,then degrading or inhibiting translation of the target mRNA.The miRNA participates in the growth and progression development of individual organism and of the disease by regulating the gene expression after transcription.Chronic lymphocytic leukemia （CLL） is a malignant proliferative disease of B lymphocytes with insidious onset,showing significant heterogeneity in the incidence of individual,disease progression,treatment response,clinical prognosis and so on.Now,more and more studies have shown that mutation or abnormal expression of miRNA are closely related to CLL occurrence,progression,prognosis and curitve efficacy.Complex and diverse miRNA in CLL may play a role of oncogenes or tumor suppressor genes.In the near future,some miRNAs may even become fresh biomarkers or therapeutic targets of CLL.This review will focus on miRNA molecules related to the pathogenesis,prognosis and treatment of CLL.

关 键 词：微小RNA 慢性淋巴细胞白血病 基因调控 靶向治疗 

分 类 号：R733.72[医药卫生—肿瘤]